Page 72 - Petelin, Ana, Nejc Šarabon, Boštjan Žvanut, eds. 2017. Zdravje delovno aktivne populacije ▪︎ Health of the Working-Age Population. Proceedings. Koper: Založba Univerze na Primorskem/University of Primorska Press
P. 72
avje delovno aktivne populacije | health of the working-age population 70 PAOLI, A., BIANCO, A., DAMIANI, E. and BOSCO, G. 2014. Ketogenic diet
in neuromuscular and neurodegenerative diseases. BioMed Research In-
ternational [electronic resource], vol. 2014, pp. 474296.
PRINS, M.L. and MATSUMOTO, J.H. 2014. The collective therapeutic poten-
tial of cerebral ketone metabolism in traumatic brain injury. Journal of Li-
pid Research, vol. 55, no. 12, pp. 2450-2457.
PROCACCIO, V. et al. 2014. Perspectives of drug-based neuroprotection tar-
geting mitochondria. Revue Neurologique, vol. 170, no. 5, pp. 390-400.
PUCHALSKA, P. and CRAWFORD, P.A. 2017. Multi-dimensional Roles of Ke-
tone Bodies in Fuel Metabolism, Signaling, and Therapeutics. Cell Metab-
olism, vol. 25, no. 2, pp. 262-284.
ROSINI, M. et al. 2014. Oxidative stress in Alzheimer’s disease: are we connect-
ing the dots? Journal of Medicinal Chemistry, vol. 57, no. 7, pp. 2821-2831.
SCHECK, A.C., ABDELWAHAB, M.G., FENTON, K.E. and STAFFORD, P.
2012. The ketogenic diet for the treatment of glioma: insights from genet-
ic profiling. Epilepsy Research, vol. 100, no. 3, pp. 327-337.
SHARMA, A., BEMIS, M. and DESILETS, A.R. 2014. Role of Medium Chain
Triglycerides (Axona(R)) in the Treatment of Mild to Moderate Alzheim-
er‘s Disease. American Journal of Alzheimer‘s Disease and Other Dementias,
vol. 29, no. 5, pp. 409-414.
STAFSTROM, C.E. and RHO, J.M. 2012. The ketogenic diet as a treatment par-
adigm for diverse neurological disorders. Frontiers in Pharmacology [elec-
tronic resource], vol. 3, pp. 59.
THIO, L.L. 2012. Neuroprotection in metabolism-based therapy. Epilepsy Re-
search, vol. 100, no. 3, pp. 286-294.
VERDILE, G., FULLER, S.J. and MARTINS, R.N. 2015. The role of type 2 di-
abetes in neurodegeneration. Neurobiology of Disease, vol. 84, pp. 22-38.
VOLEK, J.S. et al. 2009. Carbohydrate restriction has a more favorable impact
on the metabolic syndrome than a low fat diet. Lipids, vol. 44, no. 4, pp.
297–309.
VOLKOW, N.D. et al. 2012. Food and drug reward: overlapping circuits in hu-
man obesity and addiction. Current Topics in Behavioral Neurosciences,
vol. 11, pp. 1-24.
WILKINS, H.M. and MORRIS, J.K. 2017. New Therapeutics to Modulate Mito-
chondrial Function in Neurodegenerative Disorders. Current Pharmaceu-
tical Design, vol. 23, no. 5, pp. 731-752.
YANCY, W.J. et al. 2010. A randomized trial of a low-carbohydrate diet vs orl-
istat plus a low-fat diet for weight loss. A. Archives of Internal Medicine, vol.
170, no. 2, pp. 136-145.
YOUM, Y.H. et al. 2015. The ketone metabolite beta-hydroxybutyrate blocks
NLRP3 inflammasome-mediated inflammatory disease. Nature Medicine,
vol. 21, no. 3, pp. 263-269.
in neuromuscular and neurodegenerative diseases. BioMed Research In-
ternational [electronic resource], vol. 2014, pp. 474296.
PRINS, M.L. and MATSUMOTO, J.H. 2014. The collective therapeutic poten-
tial of cerebral ketone metabolism in traumatic brain injury. Journal of Li-
pid Research, vol. 55, no. 12, pp. 2450-2457.
PROCACCIO, V. et al. 2014. Perspectives of drug-based neuroprotection tar-
geting mitochondria. Revue Neurologique, vol. 170, no. 5, pp. 390-400.
PUCHALSKA, P. and CRAWFORD, P.A. 2017. Multi-dimensional Roles of Ke-
tone Bodies in Fuel Metabolism, Signaling, and Therapeutics. Cell Metab-
olism, vol. 25, no. 2, pp. 262-284.
ROSINI, M. et al. 2014. Oxidative stress in Alzheimer’s disease: are we connect-
ing the dots? Journal of Medicinal Chemistry, vol. 57, no. 7, pp. 2821-2831.
SCHECK, A.C., ABDELWAHAB, M.G., FENTON, K.E. and STAFFORD, P.
2012. The ketogenic diet for the treatment of glioma: insights from genet-
ic profiling. Epilepsy Research, vol. 100, no. 3, pp. 327-337.
SHARMA, A., BEMIS, M. and DESILETS, A.R. 2014. Role of Medium Chain
Triglycerides (Axona(R)) in the Treatment of Mild to Moderate Alzheim-
er‘s Disease. American Journal of Alzheimer‘s Disease and Other Dementias,
vol. 29, no. 5, pp. 409-414.
STAFSTROM, C.E. and RHO, J.M. 2012. The ketogenic diet as a treatment par-
adigm for diverse neurological disorders. Frontiers in Pharmacology [elec-
tronic resource], vol. 3, pp. 59.
THIO, L.L. 2012. Neuroprotection in metabolism-based therapy. Epilepsy Re-
search, vol. 100, no. 3, pp. 286-294.
VERDILE, G., FULLER, S.J. and MARTINS, R.N. 2015. The role of type 2 di-
abetes in neurodegeneration. Neurobiology of Disease, vol. 84, pp. 22-38.
VOLEK, J.S. et al. 2009. Carbohydrate restriction has a more favorable impact
on the metabolic syndrome than a low fat diet. Lipids, vol. 44, no. 4, pp.
297–309.
VOLKOW, N.D. et al. 2012. Food and drug reward: overlapping circuits in hu-
man obesity and addiction. Current Topics in Behavioral Neurosciences,
vol. 11, pp. 1-24.
WILKINS, H.M. and MORRIS, J.K. 2017. New Therapeutics to Modulate Mito-
chondrial Function in Neurodegenerative Disorders. Current Pharmaceu-
tical Design, vol. 23, no. 5, pp. 731-752.
YANCY, W.J. et al. 2010. A randomized trial of a low-carbohydrate diet vs orl-
istat plus a low-fat diet for weight loss. A. Archives of Internal Medicine, vol.
170, no. 2, pp. 136-145.
YOUM, Y.H. et al. 2015. The ketone metabolite beta-hydroxybutyrate blocks
NLRP3 inflammasome-mediated inflammatory disease. Nature Medicine,
vol. 21, no. 3, pp. 263-269.
